/Medical%20lab%20microscope%20chemistry%20biology%20test%20by%20Shutter2U%20via%20Adobe%20Stock.jpeg)
The biotechnology sector has long rewarded companies that can translate early clinical promise into late-stage validation, and nowhere is that dynamic more pronounced than in oncology. Acute myeloid leukemia (AML) remains one of the most challenging cancers to treat, with limited durable options for patients who relapse after standard therapy.
That unmet need has made AML-focused immunotherapy a magnet for both strategic pharmaceutical partnerships and investor capital willing to underwrite clinical-stage risk in exchange for outsized upside potential. SELLAS Life Sciences Group, Inc. (SLS) sits squarely within this high-stakes corner of the market.
